Angiotensin ‐converting enzyme inhibitors and angiotensin II receptor blockers are not associated with severe COVID‐19 infection in a multi‐site UK acute hospital trust

ConclusionsThere was no evidence for increased severity of COVID ‐19 in hospitalised patients on chronic treatment with ACEi or ARB. A trend towards a beneficial effect of ACEi/ARB requires further evaluation in larger meta‐analyses and randomised clinical trials.

Source: European Journal of Heart Failure - July 6, 2020 Category: Cardiology Authors: Daniel M. Bean, Zeljko Kraljevic, Thomas Searle, Rebecca Bendayan, O'Gallagher Kevin, Andrew Pickles, Amos Folarin, Lukasz Roguski, Kawsar Noor, Anthony Shek, Rosita Zakeri, Ajay M. Shah, James T.H. Teo, Richard J.B. Dobson Tags: Research Article Source Type: research